The HCPLive Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.
November 22nd 2024
A study identified homelessness and minority status as factors that impact clozapine prescription patterns.
November 14th 2024
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Prenatal Depression Linked to Increased Cardiovascular Risk Within First 2 Years After Delivery
April 28th 2023An analysis of data from more than 119,000 pregnancies suggests women with prenatal depression were at increased risk for multiple forms of cardiovascular disease within the first 2 years following delivery relative to their counterparts without prenatal depression.
Treatment with benzodiazepines, antipsychotics, and antidepressants was associated with an increased risk of all-cause hospitalization or mortality, while mood stabilizer treatment did not have a statistically significant association with any of the predetermined outcomes and ADHD medications were linked to a lower risk of psychiatric hospitalization.
SNAP Program Leads to Less Food Insecurity, Mental Illness Rates
State adoption of both SNAP eligibility policies, where the state eliminates the asset test and increases the income limit resulted in decreases in the rates of past-year major depressive episodes, mental illness, serious mental illness, and suicidal ideation.
Electroconvulsive Therapy Bests Ketamine in Treating Major Depressive Episodes
Electroconvulsive therapy was superior to ketamine in a sensitivity analysis of methodologically stronger trials and also was better in study-defined response and remission for patients with major depressive episodes.
fNIRS Investigation of Brain Activity, Cognitive Function and Sleep Quality in Major Depression
April 6th 2023A new study has found individuals with depression and insomnia show significantly less activity in the prefrontal cortex during verbal fluency tests, suggesting that sleep quality is an important indicator in fNIRS screening.
Investigators Identify Risk Factors for Drug-Induced Parkinsonism for Schizophrenia Patients
Various psychiatric symptoms, including more severe negative symptoms, lower cognition status, and lower excited symptoms were significantly linked to drug-induced parkinsonism induction.
FDA Will Not Hold Advisory Meeting for MDD, PPD Drug Application
Zuranolone is being evaluated as a 14 day, rapid-acting, once-daily, oral treatment for adult patients with MDD and PPD. The drug is an oral neuroactive steroid GABA-A receptor positive allosteric modulator.
New Research Seeks Explanation of Antidepressant Placebo Effect
The results from a Bayesian reinforcement learning model showed the antidepressant placebo trial-wise expectancies were updated by composite learning signals multiplexing sensory evidence and trial-wise mood.